Summit Therapeutics Appoints Mr David Wurzer as a Non-Executive Director

Accessibility: Skip TopNav

February 23, 2015 02:01 ET

Summit Therapeutics plc

Summit Therapeutics plc

Summit Therapeutics plc

('Summit' or the 'Company')

SUMMIT APPOINTS MR DAVID WURZER AS NON-EXECUTIVE DIRECTOR

Oxford, UK, 23 February 2015 - Summit Therapeutics plc (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection ('CDI'), announces the appointment of Mr David Wurzer as a Non-Executive Director.

"David Wurzer has extensive skills and expertise from his career in the pharmaceutical and biotechnology industry, and, on behalf of Summit, I am delighted to welcome him to the Board of Directors," commented Dr Frank Armstrong, Chairman of Summit.  "This is an exciting time for the company as we continue to explore a possible listing on NASDAQ to complement our existing AIM listing, as well as advance our DMD and CDI programmes through patient clinical trials.  David's expertise in financial matters and experience in working for US listed companies will be extremely valuable in supporting the future growth of the Company."

Mr David Wurzer added, "I am very pleased to be joining Summit at this exciting and important period in its development.  I very much look forward to working with the experienced board and management team at Summit as we seek to establish the benefit of our innovative DMD and CDI programmes as potential life-changing treatments."

About Mr David Wurzer (aged 56)

Mr David Wurzer has extensive experience in business and financial matters relating to the pharmaceutical and biotechnology sector having held a number of senior executive and board level positions.  Mr Wurzer was Executive Vice President, Treasurer and Chief Financial Officer of the NASDAQ listed biotechnology company CuraGen Corporation from 1997 to 2008.   He also held a number of positions at Value Health Inc., from 1991 to 1997 including Senior Vice President, Treasurer and Chief Financial Officer.  He is currently the Executive Vice President and Chief Investment Officer at Connecticut Innovations, a state funded venture capital fund.  Mr. Wurzer is currently a Non-Executive Director on the boards of Response Genetics and Special Diversified Opportunities, Inc., and from 2010 to 2012 he was a Non-Executive Director on the board of DUSA Pharmaceuticals.  Mr. Wurzer is a Certified Public Accountant and began his career with Coopers & Lybrand, which is now part of PricewaterhouseCoopers. He received a BBA from the University of Notre Dame.

Mr Wurzer has notified the Company of the following:

There is no other information required to be disclosed under Schedule 2 paragraph (g) or Rule 17 of the AIM Rules.

About Summit Therapeutics

Summit is a drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.  Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.  Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Forward Looking Statements

This announcement contains "forward-looking statements", including, but not limited to, statements about the discovery, development and commercialisation of programme assets. These forward-looking statements are statements based on the Company's current intentions, beliefs and expectations, which include, among other things, the Company's results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. No forward-looking statement is a guarantee of future performance and actual results could differ materially from those expressed or implied in the forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements or information.  Forward-looking statements and information by their nature involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These include but are not limited to: adverse results in clinical or preclinical development studies; delays in obtaining regulatory approval; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; being unable to secure partnership agreements to develop and commercialise programme assets; being unable to secure the necessary funding to conduct any proposed research and development studies; and the ability to retain and recruit key personnel.  The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this announcement to reflect any changes in expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based, except as required by applicable law.